SciCombinator

Discover the most talked about and latest scientific content & concepts.

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

The New England journal of medicine | 1 Oct 2019

R de Wit, J de Bono, CN Sternberg, K Fizazi, B Tombal, C Wülfing, G Kramer, JC Eymard, A Bamias, J Carles, R Iacovelli, B Melichar, Á Sverrisdóttir, C Theodore, S Feyerabend, C Helissey, A Ozatilgan, C Geffriaud-Ricouard and D Castellano
Abstract
The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.
Tweets*
80
Facebook likes*
0
Reddit*
0
News coverage*
89
Blogs*
0
SC clicks
0
Concepts
-
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com